Stock analysts at BTIG Research began coverage on shares of CeriBell (NASDAQ:CBLL - Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a "buy" rating and a $30.00 price target on the stock. BTIG Research's price objective indicates a potential upside of 60.79% from the stock's previous close.
Several other equities analysts have also recently commented on the stock. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell has an average rating of "Buy" and a consensus price target of $32.14.
Read Our Latest Research Report on CBLL
CeriBell Stock Down 3.3%
Shares of CBLL stock traded down $0.63 during trading on Tuesday, reaching $18.66. 151,472 shares of the company's stock were exchanged, compared to its average volume of 281,720. The company has a quick ratio of 16.81, a current ratio of 17.36 and a debt-to-equity ratio of 0.11. The firm's fifty day moving average price is $17.03 and its 200-day moving average price is $20.47. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to the consensus estimate of $19.30 million. As a group, research analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.
Insider Transactions at CeriBell
In related news, CEO Xingjuan Chao sold 5,700 shares of the business's stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the sale, the chief executive officer now owns 746,451 shares in the company, valued at $11,211,694.02. The trade was a 0.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Rebecca B. Robertson sold 7,445 shares of the stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $17.63, for a total value of $131,255.35. Following the completion of the transaction, the director now owns 21,230 shares of the company's stock, valued at $374,284.90. This represents a 25.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,333 shares of company stock worth $1,895,195. Corporate insiders own 20.10% of the company's stock.
Institutional Investors Weigh In On CeriBell
A number of institutional investors have recently added to or reduced their stakes in CBLL. Legal & General Group Plc acquired a new position in shares of CeriBell during the fourth quarter worth $32,000. Summit Investment Advisors Inc. bought a new position in shares of CeriBell during the fourth quarter worth about $33,000. Tower Research Capital LLC TRC acquired a new position in shares of CeriBell in the fourth quarter worth approximately $37,000. BNP Paribas Financial Markets bought a new stake in CeriBell in the fourth quarter valued at approximately $43,000. Finally, PNC Financial Services Group Inc. bought a new position in CeriBell during the 4th quarter worth approximately $47,000.
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
